Apatinib for molecular targeted therapy in tumor

Haijun Zhang
Department of Oncology, Zhongda Hospital, Medical School, Southeast University, Nanjing, People’s Republic of China

Abstract: As tumor angiogenesis is one of the hallmarks of cancer, the inhibition of vascular endothelial growth factor signaling has become an attractive anticancer approach. Apatinib, a small-molecule inhibitor of vascular endothelial growth factor receptor-2, has demonstrated encouraging anticancer activity across a broad range of malignancies, including gastric cancer, non-small-cell lung cancer, breast cancer, and hepatocellular carcinoma. In this up-to-date review, focus is not only on the structure, mechanisms, and pharmacokinetics of apatinib, but also on summarizing clinical trials and making recommendations of apatinib for patients with advanced solid tumors.

Keywords: apatinib, angiogenesis, vascular endothelial growth factor receptor-2, molecular targeted therapy, tumor

Introduction
Angiogenesis is an essential step in tumor growth and metastasis.1–5 Vascular endothelial growth factor (VEGF) signaling plays an important role in angiogenesis, and vascular endothelial growth factor receptors (VEGFRs) are tyrosine kinases functioning as key regulators of this process. Therefore, they may represent potential targets for anticancer therapy. The VEGFR family proteins consist of VEGFR-1 (FMS-like tyrosine kinase [FLT]-1), VEGFR-2 (KDR/Flik-1), and VEGFR-3 (FLT-4).6 Among them, VEGFR-2 is the principal mediator of the VEGF-induced angiogenic signaling. Thus, as a novel target, the blockage of VEGFR-2 could be a promising strategy to inhibit tumor-induced angiogenesis.7 Various VEGFR-2 inhibitors, including receptor-specific antibodies and low molecular weight chemicals such as sorafenib, vandetanib, cediranib, and sunitinib have recently been developed.8–10 Moreover, apatinib is a small molecule that may specifically bind VEGFR-2, which could inhibit VEGF-stimulated endothelial cell migration and proliferation and decrease tumor microvascular density.11,12

Apatinib, also known as YN968D1, is one of the latest orally angiogenic agents with encouraging preclinical and clinical data in the treatment of a variety of solid tumors. It was approved and launched in People’s Republic of China in 2014 as a subsequent-line treatment for patients with gastric cancer (AGC). In addition, it is also currently undergoing Phase II/III clinical trials in People’s Republic of China for the treatment of many cancer types, such as non-small-cell lung cancer (NSCLC), breast cancer, and hepatocellular carcinoma. These clinical trials demonstrate that apatinib has potential antitumor activity across a broad range of advanced solid tumors.

In this review, the structure, mechanisms, and pharmacokinetics of apatinib are addressed. Clinical trials are also summarized and recommendations are made of apatinib for patients with AGC and other cancer types.
**Structure and mechanism**

Apatinib is a small-molecule antiangiogenic agent (molecular weight 493.58 Da) that selectively inhibits VEGFR-2 and also mildly inhibits c-Kit and c-Src tyrosine kinases.\(^{11}\) The molecular formula of apatinib is C\(_{25}\)H\(_{27}\)N\(_{5}\)O\(_{4}\)S, and chemical formula is \(N\)\(^{-}\)\([4-(1\text{-cyano-cyclopentyl})\text{phenyl}]\)\(^{-}\)2-(4-pyridylmethyl) amino-3-pyridine carboxamide, which is shown in Figure 1. As is well known, VEGF signaling plays an important role in the angiogenic process of solid tumors. When stimulated by VEGF, VEGFR-2 is auto-phosphorylated at the carboxy terminal tail and kinase-insert region, which is the most pro-angiogenic effect.\(^{11,13}\)

The phosphorylation of specific sites creates binding sites for the SH\(_{3}\) domains of various signaling molecules and has subsequent effects of cell proliferation, migration, permeability, and survival on the vascular endothelium.\(^{7,11}\)

Different tyrosine kinase inhibitors of VEGFRs do not have the same spectrum of molecular targets: apatinib with VEGFR-2, c-Kit, Ret, and c-Src; sorafenib with VEGFR-1/2/3, platelet-derived growth factor receptor (PDGFR)-\(\beta\), c-Kit, FLT-3, and Ret; sunitinib with VEGFR-1/2/3, PDGFR-\(\alpha/\beta\), c-Kit, FLT-3, and Ret; pazopanib with VEGFR-1/2/3, PDGFR-\(\alpha/\beta\), fibroblast growth factor receptor-1/2, and c-Kit; axitinib with VEGFR-1/2/3; tivozanib with VEGFR-1/2/3; and vandetanib with VEGFR-2, epidermal growth factor receptor (EGFR)-2, and Ret.\(^{14}\) By binding to VEGFR-2, apatinib inhibits the effects of VEGF binding and subsequent VEGFR-2 autophosphorylation.\(^{14}\)

In addition, apatinib-mediated VEGFR-2 inhibition also appears to inhibit downstream phosphorylated extracellular signal-regulated kinase. Through this inhibition, apatinib plays antiangiogenic and antitumor roles.\(^{14}\) Figure 2 schematically illustrates the possible mechanism of apatinib as the inhibitor of VEGFR-2.

**Chemical structure of apatinib.**

**Pharmacokinetics**

Pharmacokinetic analysis by Li et al showed that the time to maximum plasma concentration level was \(-4\) hours after dose and the mean half-life was 9 hours.\(^{12}\) In three separate dosing groups, 500 mg \((n=8)\), 750 mg \((n=12)\), and 800 mg \((n=8)\), of 28 patients enrolled into a single dose arm, the \(C_{\text{max}}\) and AUC\(_{24}\) values were dose-dependent and demonstrated variability among patients with \(C_{\text{max}}\) of 1,521, 2,379, and 2,833 ng/mL and AUC\(_{24}\) of 11,295, 18,172, and 21,975 ng*h/mL, respectively.\(^{6}\) Steady-state conditions analysis of eleven patients enrolled in the multidose cohort suggested no accumulation during 56 days once a day administration of 750 mg apatinib.\(^{12}\)

The primary routes of apatinib biotransformation include \(E\)\(- and \(Z\)-cyclopentyl-3-hydroxylation, \(N\)-dealkylation, pyridyl-25-N-oxidation, 16-hydroxylation, dioxygenation, and \(O\)-glucuronidation after 3-hydroxylation.\(^{15}\) Nine major metabolites were confirmed, of which \(E\)-3-hydroxy-apatinib-\(O\)-glucuronide (M9-2) was the major circulating metabolite.\(^{11}\) The total recovery of the administered dose was 76.8% within 96 hours postdose, with 69.8% and 7.02% of the administered dose excreted in feces and urine, respectively.\(^{15}\)

**Preclinical research**

Several basic studies have been dedicated to the antitumor activity of apatinib in vitro and in vivo. In vitro, apatinib potently suppressed the kinase activities of VEGFR-2, c-Kit, and c-Src, and inhibited cellular phosphorylation of VEGFR-2, c-Kit, and PDGFRb.\(^{11}\) Apatinib could also effectively inhibit proliferation, migration, and tube formation of human umbilical vein endothelial cells induced by fetal bovine serum, and block the budding of rat aortic ring.\(^{11}\) Encouraged by the remarkable inhibitory activity against VEGFR-2 tyrosine kinase in vitro, Tian et al further performed the investigation of the potential antitumor effect of apatinib in vivo.\(^{11}\) The results demonstrated that apatinib showed antitumor efficacy in vivo when administrated alone or in combination with chemotherapy against a variety of established tumor xenografts with good tolerance.\(^{11}\) To date, the outcome of cancer chemotherapy still encounters two major challenges: nonspecific targets and multidrug resistance (MDR). In fact, more than 90% of patients with malignant tumors die of MDR.\(^{16,17}\) Apatinib could also reverse cancer MDR mediated by MDR protein 1 (ABCB1), MDR-associated protein 1 (MARPI), and breast cancer resistant protein (BCRP) through inhibiting their transport function as well.\(^{18,19}\) Thus, apatinib may be useful in overcoming MDR to other conventional antineoplastic drugs.
Apatinib for molecular targeted therapy in tumor

The efficacy of apatinib for the treatment of a variety of solid tumors has been investigated in several clinical trials, including various Phase I, II, and III studies on registry, which is summarized in Table 1.

Phase I

Phase I study of apatinib as an inhibitor of angiogenesis by Jin Li as principal investigator was conducted to determine the maximum tolerated dose, safety profile, pharmacokinetic variables, and antitumor activity in advanced solid malignancies (NCT00633490). In this study, 46 patients with advanced cancer were enrolled, including 34 cases of gastrointestinal cancer, three cases of lung cancer, three cases of breast cancer, and six cases of other tumor types. The maximum tolerated dose was determined to be 850 mg qd. The recommended dose was 750 mg qd, which could be well tolerated. Besides, among 37 evaluable patients, partial response was noted in seven patients (18.9%) and stable disease in 24 (64.9%), with a disease control rate (DCR) of 83.8% at 8 weeks. The safety profile was acceptable and the regimen was also well tolerated.

Table 1 Characteristics of the clinical trials of apatinib for molecular targeted therapy in tumor

<table>
<thead>
<tr>
<th>Study</th>
<th>Trial</th>
<th>Design</th>
<th>Tumor type</th>
<th>Outcomes (apatinib vs placebo)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Li et al(^1)</td>
<td>Phase I</td>
<td>Dose escalation</td>
<td>Advanced solid tumors</td>
<td>MTD: 850 mg qd</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Recommended dose: 750 mg qd</td>
</tr>
<tr>
<td>Li et al(^2)</td>
<td>Phase II</td>
<td>Randomized, placebo-controlled, parallel-arm</td>
<td>Gastric cancer</td>
<td>mPFS: 3.67 vs 1.40 months</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>mOS: 4.83 vs 2.50 months</td>
</tr>
<tr>
<td>Hu et al(^3)</td>
<td>Phase II</td>
<td>Prospective, open-label, single arm</td>
<td>Triple-negative breast cancer</td>
<td>mPFS: 3.3 months</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>mOS: 10.6 months</td>
</tr>
<tr>
<td>Hu et al(^4)</td>
<td>Phase II</td>
<td>Multicenter, open-label, single arm</td>
<td>Non-triple-negative breast cancer</td>
<td>mPFS: 4.0 months</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>mOS: 10.3 months</td>
</tr>
<tr>
<td>Zhang et al(^5)</td>
<td>Phase II</td>
<td>Multicenter, randomized, placebo-controlled</td>
<td>Non-small-cell lung cancer</td>
<td>mPFS: 4.7 vs 1.9 months</td>
</tr>
<tr>
<td>Qin(^6)</td>
<td>Phase III</td>
<td>Randomized, multicenter, double-blind, placebo-controlled</td>
<td>Gastric cancer</td>
<td>mOS: 195 vs 140 days</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>mPFS: 78 vs 53 days</td>
</tr>
</tbody>
</table>

Notes: \(^1\): 850 mg of apatinib qd; \(^2\): apatinib 425 mg bid.

Abbreviations: MTD, maximum tolerated dose; mPFS, median progression-free survival; mOS, median overall survival; bid, twice a day; qd, once a day.

Figure 2 Schematic illustration of the possible mechanism of apatinib as the inhibitor of VEGFR-2.

Notes: By specifically binding to the phosphorylation sites of VEGFR-2, apatinib inhibits the subsequent effects on the vascular endothelium, including cell proliferation, migration, permeability, and survival. Through this inhibition, apatinib plays an antiangiogenic role.

Abbreviations: VEGFR-2, vascular endothelial growth factor receptor-2; VEGF, vascular endothelial growth factor.
well tolerated. The most frequently observed drug-related adverse events were hypertension (69.5%, 29 grade 1–2 and three grade 3–4), proteinuria (47.8%, 16 grade 1–2 and six grade 3–4), and hand–foot syndrome (45.6%, 15 grade 1–2 and six grade 3–4).

**Phase II**

**Apatinib for AGC/mGC**

Gastric cancer is the third most common cause of cancer-related death in the world. Although there is a better chance of recovery in early gastric cancer, the prognosis of patients with metastatic or AGC remains poor, with a median overall survival (mOS) of 1 year. There may be clinical remission or disease stabilization in AGC patients who receive first-line chemotherapy; however, most will ultimately experience disease progression, and thus effective second-line chemotherapy is essential. However, after failure of second-line chemotherapy, the outcomes of further treatment are poor, yielding response rates of 0%–5% without evidence of prolonged survival. Therefore, novel and more effective treatment options are urgently needed to provide survival benefit for patients with AGC or metastatic gastric cancer (mGC). Fortunately, apatinib is a new therapy option providing hope for patients with AGC or mGC who have previously failed second-line chemotherapy.11 In a randomized, placebo-controlled, parallel-arm Phase II trial (NCT00970138), Li et al evaluated apatinib as a subsequent-line therapy for patients with histologically confirmed AGC or mGC.22 In the trial, 144 enrolled patients were divided into three groups: placebo (group A), 850 mg of apatinib qd (group B), and apatinib 425 mg bid (group C). Progression-free survival (PFS) was the primary end point. Secondary end points included DCR, objective response rate, overall survival, and quality of life. The outcomes demonstrated that the median progression-free survival (mPFS) for groups A, B, and C was 1.40 months (95% confidence interval [CI]: 1.20–1.83 months), 3.67 months (95% CI: 2.17–6.80 months), and 3.20 months (95% CI: 2.37–4.53 months), respectively. mOS for groups A, B, and C was 1.40 months (95% CI: 1.87–3.70 months), 4.83 months (95% CI: 4.03–5.87 months), and 4.27 months (95% CI: 3.83–4.77 months), respectively. There were statistically significant differences between the apatinib groups and the placebo group in PFS and overall survival (P<0.001). But, there was no significant difference between apatinib 425 mg bid vs 850 mg qd (hazard ratio [HR]:1.22; 95% CI: 0.68–2.20; P<0.551). These results illustrated that apatinib showed improved PFS and overall survival in heavily pretreated patients with AGC or mGC who had experienced treatment failure with two or more chemotherapy regimens.

**Apatinib for TNBC and non-TNBC**

Breast cancer is the most common malignancy in women worldwide. Although 5-year recurrence rates and 15-year mortality rates could benefit from effective chemotherapy and hormonal therapy for early breast cancer, many patients still experience tumor relapse or metastasis. In addition to chemotherapy, endocrine therapy or targeted human EGFR-2 therapy plays an important role of the therapy for patients with metastatic non-triple-negative breast cancer (TNBC); however, most patients will eventually develop drug resistance. Metastatic TNBC is also particularly challenging due to the lack of recognized therapeutic molecular biology targets, which is highly proliferative, with a high risk for recurrence, relatively poorer prognosis, and rapid disease progression. Novel drugs for such patients with metastatic breast cancer are therefore needed urgently. To solve it, a prospective, open-label, Phase II trial by Hu et al aimed to evaluate the efficacy and safety of apatinib in heavily pretreated patients with metastatic TNBC (NCT01176669). In the trial, after the optimum dose level of 500 mg/day was recommended by Phase IIa, a Phase IIb study of 59 patients with metastatic TNBC was activated, with the endpoint PFS. The outcomes were reported that mPFS and mOS were 3.3 months (95% CI: 1.7–5.0 months) and 10.6 months (95% CI: 5.6–15.7 months), respectively. In the 56 evaluable patients, overall response and clinical benefit rates were 10.7% and 25.0%, respectively. As for adverse events, the most common grade 3/4 hematologic toxicities were thrombocytopenia (13.6%), leukopenia (6.8%), neutropenia (3.4%), and anemia (1.7%). The most frequent grade 3/4 nonhematologic toxicities were hand–foot syndrome, proteinuria, hypertension, and increased alanine aminotransferase. In the last decade, several multiple kinase inhibitors of VEGFR, such as sunitinib and sorafenib, have been developed for the antiangiogenic therapy of TNBC. There is minor difference when apatinib is compared with these multiple kinase inhibitors while sunitinib and sorafenib have demonstrated modest single-agent activity but improved outcomes combined with chemotherapy. As for the efficacy of apatinib on heavily pretreated, metastatic non-TNBC, another multicenter, open-label, single arm, Phase II trial study was performed. Inclusion criteria included patients who failed in the metastatic setting of at least one and at most four prior chemotherapy regimens,
hormone receptor-positive patients who received at least one endocrine drug, and human EGFR-2-positive patients who were treated with at least one anti-human EGFR-2 drug. There were 38 enrolled patients who received apatinib for a median of 4 cycles (range from 0 to 10 cycles). In the study, mPFS was 4.0 months (95% CI: 2.8–5.2 months) and mOS was 10.3 months (95% CI: 9.1–11.6 months). In all, 36 patients were eligible for efficacy analysis, with an objective response rate of 16.7% (6/36) and DCR of 66.7% (24/36). Adverse events were also observed, and the most common grade 3 or 4 nonhematologic ones were hypertension (20.5%), hand-foot syndrome (10.3%), and proteinuria (5.1%).

Apatinib for advanced NSCLC

Lung cancer is a leading cause of cancer-related mortality that accounts for 13% and 18% of all cancer-related cases and deaths, respectively, in the world. Approximately, 80%–85% of lung cancer cases are NSCLC. Unfortunately, 75% of NSCLC patients present with locally advanced or metastatic disease at the time of diagnosis. Although surgical excision and chemotherapy are attainable in some patients with advanced NSCLC, the therapeutic options for locally advanced or metastatic disease remain limited. In recent years, targeted drugs shift the traditional treatment mode of NSCLC, including apatinib. A multicenter, randomized, placebo-controlled, Phase II trial by Zhang et al was to determine whether apatinib could improve PFS compared with placebo in patients with advanced nonsquamous NSCLC who failed two lines of treatment (NCT01270386). In the study, 135 patients were randomized in a 2:1 fashion to apatinib 750 mg qd vs placebo until disease progression or unacceptable toxicity. As expected, mPFS was 4.7 months for apatinib group vs that of 1.9 months for placebo group with an HR of 0.278 (95% CI: 0.170–0.455) (P<0.0001). The response rate and DCR were also significantly better in apatinib arm (12.2% and 68.9%) than in placebo arm (0% and 24.4%) (P=0.0158 and P<0.0001). Although hypertension, proteinuria, and hand-foot syndrome were the most frequent adverse events, they were generally mild or moderate in severity and were manageable. In summary, the Phase II trial shows that apatinib has substantial clinical activity without significant additional toxicity in patients with advanced NSCLC.

Phase III

As illustrated above, apatinib provides a new treatment option and leads a new hope for patients with advanced or mGC. Further study was carried out based on Phases I and II. A randomized, multicenter, double-blind, placebo-controlled Phase III trial by Qin investigated single-agent apatinib in patients with AGC who previously failed to second-line chemotherapy (NCT01512745). Patients were randomized in a 2:1 fashion to apatinib 850 mg qd or placebo with a planned total enrollment of 270 patients. As for the efficacy, patients treated with apatinib at the dose of 850 mg qd had significantly prolonged mOS (195 vs 140 days; HR =0.71, 95% CI: 0.54–0.94; P<0.016) and mPFS (78 vs 53 days; HR =0.44, 95% CI: 0.33–0.61; P<0.0001) compared with those treated with placebo. The objective response rate of apatinib group and placebo group were 2.84% and 0.00%, respectively. Hypertension, hand-foot syndrome, proteinuria, fatigue, anorexia, and elevated aminotransferase were grade 3/4 adverse reactions observed in more than 2% of patients, which could be managed by dose interruptions or reductions. Given the excellent results obtained in the Phase III trial, apatinib offers a new treatment option for patients with advanced mGC.

Ongoing trials

Currently, there are also multiple ongoing clinical trials investigating apatinib for molecular targeted therapy in tumor. For example, a double-blind, placebo-controlled, Phase III study explores apatinib for patients with EGFR wild-type nonsquamous NSCLC (NCT 02332512). Phase II and Phase III trials investigating apatinib in subsequent-line treatment for hepatocellular carcinoma are also actively recruiting (NCT02329860).

Side effects of apatinib treatment

Apatinib is generally well tolerated by patients. However, adverse effects also occurred, and these are considered manageable. The most frequently observed drug-related adverse events were hypertension, proteinuria, and hand-foot syndrome. Management of these toxicities could include dose reduction, interruption, or termination.

Conclusion and future directions for drug development

Apatinib is a novel, orally bioavailable small-molecule tyrosine kinase inhibitor of VEGFR-2 that appears to be a promising agent in the treatment of a variety of tumor types, and has demonstrated improved outcomes and a tolerable safety profile in subsequent-line therapy. Since single modality has not always been sufficiently effective, combination therapies are the solution to improve
the outcome of treatment. However, Lin et al reported that apatinib combined with elemene injection (a Chinese medicine) for the treatment of H22 solid tumor in mice resulted in worse effectiveness than apatinib alone.35 Thus, the multiple therapeutics strategies of apatinib combined with other therapies, such as chemotherapy and radiotherapy, should be implemented and developed in future clinical trials to address these issues. Besides, to find biomarkers to predict drug efficacy is also one of the challenges with antiangiogenic therapies using apatinib. Predictive biomarkers could discriminate patients who are most likely to be sensitive to apatinib and avoid exposure to useless toxic medicine.36 Thus, additional studies into biomarkers may be useful in predicting personalized therapeutic response.

Acknowledgments
This work was supported by the National Natural Science Foundation of China (31200750, 81371678) and the Natural Science Foundation of Jiangsu Province (BK2012332).

Disclosure
The author reports no conflicts of interest in this work.

References